November 25, 2022

MultiplexDX was awarded two prizes by the Deloitte Technology Fast 50

The programme Deloitte Technology Fast 50 recognizes the fastest-growing technology companies in Central Europe. Percentage revenue growth is the primary indicator that determines the final ranking for the companies. Our 6222% growth between 2018 and 2021 enabled us to gain this remarkable achievement in massive competition with other 400 registered companies. The numbers of sales and revenues of our PCR tests which we developed and produced are just a reflection of the enormous effort of the entire MultiplexDX team.

At the same time we were honored to win the Impact star category. MultiplexDX is trying to have a positive impact in numerous fields. Even though the company has been driven from the beginning by the most fundamental innovation piece, to bring its revolutionary technologies to the market of personalized molecular diagnostics in cancer – we stand by our other fundamental pillars, which are our society, environment, and diversity.

The last night we spent together with other finalists celebrated our team's success and reminded us of how immense biotech potential might be.

For more info, visit - Technology Fast 50 2022 (

About MultiplexDX

MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).

MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter

Other latest

MultiplexDX News